NSG 552 Psychopharmacology Exam 1 - Modules 1-
3(2025) Actual Exam Questions and Answers A+ Graded
1. Pharmacokinetics: .Studies .how .the .body .acts .on .the .drug
2. Pharmacodynamics: .Studies .how .the .drug .acts .on .the .body
3. First-generation .antipsychotic: .- .first .developed .in .the .1950s, .first .available
. treatment .for .psychosis .- .aka .typical .antipsychotics
- increased .risk .for .EPS, .Tardive .dyskinesia
- d2 .blocker
- Currently .11 .FDA-approved .and .commerically .available .FGAs
- Most .common .differences .between .individual .FGAs .are .their .potency .and .side
. effects
- examples .include .Thorazine .(chlorpromazine), .Haldol .(haloperidol), .Prolixin
. (fluphenazine), .perphenazine .(Trilafon
4. Second-generation .antipsychotic: .- .examples .include .Abilify .(aripiprazole),
. Seroquel .(quetiapine), .Zyprexa .(olanzapine), .Risperdal .(risperidone), .Clozaril
. (clozapine)
- lower .risk .of .EPS .symptoms .compared .to .1st .gen
- higher .risk .of .metabolic .side .effects
- serotonin-dopamine .receptor .antagonists
- AKA .atypical .antipsychotics
5. EPS: .Involuntary .movements .that .occur .as .a .side .effect .to .certina .medications.
. AKA .drug .induced .movement .disorder. .May .include .tardive .dyskinesia, .dystonic
. reactions, .parkinsons-like .symptoms, .akathesia, .NMD, .akinesia
- Can .be .acute .or .chronic
,1 ./ .23
, NSG 552 Psychopharmacology Exam 1 - Modules 1-3
. . . . . . .
- related .to .suppression .of .D2 .dopamine .receptors .in .the .nigrostriatal .pathway
6. Tardive .dyskinesia: .- .characterized .by .involuntary .movments .in .the .face .and
. body
- often .induced .by .long-term .use .of .anitpsychotic .drugs
- can .be .associated .with .use .of .other .medication .types .(antidepressants, .lithium,
. antihistamines)
- more .common .with .1st .gen .antipsychotics
- movements .may .include: .writhing, .mouth .puckering, .tongue .rolling, .lip .smacking,
. pill .rolling, .tongue .protrusion
7. Upregulation: .Refers .to .the .activiation .of .the .nervous .system. .Is .the .process
. by .which .a .cell .increases .its .response .to .a .subtance .or .signal .from .outside .the .cell
. to .carry .out .a .specific .response
8. downregulation: .Refers .to .state .of .calm/relation .within .nervous .system.
. Characterized .by .a .decreased .response .by .a .cell .to .a .molecule .or
. neurotransmitter.
9. Receptor .Profiles: .FGA .- .Primarily .D2 .antagonism. .Also .antagonize .M2, .H1,
. and .a1 .receptors
SGA .- .5-HT2A .& .D2 .antagonism. .Rapid .D2 .dissociation. .5HT2A .agonism. .Also
. antagonizes .M2, .H1, .5HT2C, .and .a1 .receptors
10. Binding: .When .a .neurotransmitter .binds .to .a .receptor .on .a .receiving .cell, .it
. causes .ion .channels .to .open .or .close.
2 ./ .23
3(2025) Actual Exam Questions and Answers A+ Graded
1. Pharmacokinetics: .Studies .how .the .body .acts .on .the .drug
2. Pharmacodynamics: .Studies .how .the .drug .acts .on .the .body
3. First-generation .antipsychotic: .- .first .developed .in .the .1950s, .first .available
. treatment .for .psychosis .- .aka .typical .antipsychotics
- increased .risk .for .EPS, .Tardive .dyskinesia
- d2 .blocker
- Currently .11 .FDA-approved .and .commerically .available .FGAs
- Most .common .differences .between .individual .FGAs .are .their .potency .and .side
. effects
- examples .include .Thorazine .(chlorpromazine), .Haldol .(haloperidol), .Prolixin
. (fluphenazine), .perphenazine .(Trilafon
4. Second-generation .antipsychotic: .- .examples .include .Abilify .(aripiprazole),
. Seroquel .(quetiapine), .Zyprexa .(olanzapine), .Risperdal .(risperidone), .Clozaril
. (clozapine)
- lower .risk .of .EPS .symptoms .compared .to .1st .gen
- higher .risk .of .metabolic .side .effects
- serotonin-dopamine .receptor .antagonists
- AKA .atypical .antipsychotics
5. EPS: .Involuntary .movements .that .occur .as .a .side .effect .to .certina .medications.
. AKA .drug .induced .movement .disorder. .May .include .tardive .dyskinesia, .dystonic
. reactions, .parkinsons-like .symptoms, .akathesia, .NMD, .akinesia
- Can .be .acute .or .chronic
,1 ./ .23
, NSG 552 Psychopharmacology Exam 1 - Modules 1-3
. . . . . . .
- related .to .suppression .of .D2 .dopamine .receptors .in .the .nigrostriatal .pathway
6. Tardive .dyskinesia: .- .characterized .by .involuntary .movments .in .the .face .and
. body
- often .induced .by .long-term .use .of .anitpsychotic .drugs
- can .be .associated .with .use .of .other .medication .types .(antidepressants, .lithium,
. antihistamines)
- more .common .with .1st .gen .antipsychotics
- movements .may .include: .writhing, .mouth .puckering, .tongue .rolling, .lip .smacking,
. pill .rolling, .tongue .protrusion
7. Upregulation: .Refers .to .the .activiation .of .the .nervous .system. .Is .the .process
. by .which .a .cell .increases .its .response .to .a .subtance .or .signal .from .outside .the .cell
. to .carry .out .a .specific .response
8. downregulation: .Refers .to .state .of .calm/relation .within .nervous .system.
. Characterized .by .a .decreased .response .by .a .cell .to .a .molecule .or
. neurotransmitter.
9. Receptor .Profiles: .FGA .- .Primarily .D2 .antagonism. .Also .antagonize .M2, .H1,
. and .a1 .receptors
SGA .- .5-HT2A .& .D2 .antagonism. .Rapid .D2 .dissociation. .5HT2A .agonism. .Also
. antagonizes .M2, .H1, .5HT2C, .and .a1 .receptors
10. Binding: .When .a .neurotransmitter .binds .to .a .receptor .on .a .receiving .cell, .it
. causes .ion .channels .to .open .or .close.
2 ./ .23
